Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends

作者：Madeline Sankaran, David V. Glidden, Robert Kohn, Trang Nguyen, Oliver Bacon, Susan Buchbinder, Monica Gandhi, Diane V. Havlir, Courtney Liebi, Anne F. Luetkemeyer, Janet Q. Nguyen, Jorge Román, Hyman Scott, Thiago S. Torres, Stephanie E. Cohen · 发表于：JAMA Internal Medicine · 年份：2025 · DOI：10.1001/jamainternmed.2024.7178 · 被引用次数：54 · 研究领域：Reproductive tract infections research、HIV/AIDS Research and Interventions、Syphilis Diagnosis and Treatment

Importance: Increasing rates of sexually transmitted infections (STIs) have been associated with rises in serious morbidity. While doxycycline postexposure prophylaxis (doxyPEP), a strategy in which individuals take doxycycline, 200 mg, after condomless sex to prevent bacterial STIs, has been shown to be efficacious in randomized clinical trials, doxyPEP's potential effect on population-level STI incidence is unknown. Objective: To assess the association of citywide doxyPEP guideline release with reported chlamydia, gonorrhea, and early syphilis cases in men who have sex with men (MSM) and in transgender women in San Francisco, California. Design, Setting, and Participants: This population-level interrupted time series analysis of reported San Francisco STI cases measured monthly cases of chlamydia, gonorrhea, and early syphilis prior to (July 2021-October 2022) and after (November 2022-November 2023) release of citywide doxyPEP guidelines in October 2022. All reported chlamydia, gonorrhea, and early syphilis cases among MSM and transgender women in San Francisco during the period of analysis were included. Data were analyzed November 2023 to July 2024. Exposure: Release of doxyPEP citywide guidelines. Main Outcomes and Measures: The primary outcome was the percentage change between projected and observed chlamydia, gonorrhea, and early syphilis cases in the 13-month postexposure period. Results: Citywide, there were 6694 cases of chlamydia, 9603 cases of gonorrhea, and 2121 ...